These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

227 related items for PubMed ID: 31365151

  • 1. Randomized controlled trial assessing the impact of everolimus and low-exposure tacrolimus on graft outcomes in kidney transplant recipients.
    Taber DJ, Chokkalingam A, Su Z, Self S, Miller D, Srinivas T.
    Clin Transplant; 2019 Oct; 33(10):e13679. PubMed ID: 31365151
    [Abstract] [Full Text] [Related]

  • 2. Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study.
    Berger SP, Sommerer C, Witzke O, Tedesco H, Chadban S, Mulgaonkar S, Qazi Y, de Fijter JW, Oppenheimer F, Cruzado JM, Watarai Y, Massari P, Legendre C, Citterio F, Henry M, Srinivas TR, Vincenti F, Gutierrez MPH, Marti AM, Bernhardt P, Pascual J, TRANSFORM investigators.
    Am J Transplant; 2019 Nov; 19(11):3018-3034. PubMed ID: 31152476
    [Abstract] [Full Text] [Related]

  • 3. Tacrolimus plus mycophenolate mofetil vs. cyclosporine plus everolimus in deceased donor kidney transplant recipients: three-yr results of a single-center prospective clinical trial.
    Favi E, Spagnoletti G, Salerno MP, Pedroso JA, Romagnoli J, Citterio F.
    Clin Transplant; 2013 Nov; 27(4):E359-67. PubMed ID: 23710603
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and Safety of Everolimus Plus Low-Dose Tacrolimus Versus Mycophenolate Mofetil Plus Standard-Dose Tacrolimus in De Novo Renal Transplant Recipients: 12-Month Data.
    Qazi Y, Shaffer D, Kaplan B, Kim DY, Luan FL, Peddi VR, Shihab F, Tomlanovich S, Yilmaz S, McCague K, Patel D, Mulgaonkar S.
    Am J Transplant; 2017 May; 17(5):1358-1369. PubMed ID: 27775865
    [Abstract] [Full Text] [Related]

  • 5. Donor-Specific Anti-Human Leukocyte Antigens Antibodies, Acute Rejection, Renal Function, and Histology in Kidney Transplant Recipients Receiving Tacrolimus and Everolimus.
    Ferreira A, Felipe C, Cristelli M, Viana L, Basso G, Stopa S, Mansur J, Ivani M, Bessa A, Ruppel P, Aguiar W, Campos E, Gerbase-DeLima M, Proença H, Tedesco-Silva H, Medina-Pestana J.
    Am J Nephrol; 2017 May; 45(6):497-508. PubMed ID: 28511172
    [Abstract] [Full Text] [Related]

  • 6. Impact of early conversion from cyclosporin to everolimus on left ventricular mass index: A randomized controlled trial.
    Krishnan A, Teixeira-Pinto A, Chan D, Chakera A, Dogra G, Boudville N, Irish A, Morgan K, Phillips J, Wong G, Lim WH.
    Clin Transplant; 2017 Oct; 31(10):. PubMed ID: 28662279
    [Abstract] [Full Text] [Related]

  • 7. Association of Clinical Events With Everolimus Exposure in Kidney Transplant Patients Receiving Low Doses of Tacrolimus.
    Shihab F, Qazi Y, Mulgaonkar S, McCague K, Patel D, Peddi VR, Shaffer D.
    Am J Transplant; 2017 Sep; 17(9):2363-2371. PubMed ID: 28141897
    [Abstract] [Full Text] [Related]

  • 8. Early conversion of pediatric kidney transplant patients to everolimus with reduced tacrolimus and steroid elimination: Results of a randomized trial.
    Tönshoff B, Ettenger R, Dello Strologo L, Marks SD, Pape L, Tedesco-Silva H, Bjerre A, Christian M, Meier M, Martzloff ED, Rauer B, Ng J, Lopez P.
    Am J Transplant; 2019 Mar; 19(3):811-822. PubMed ID: 30125462
    [Abstract] [Full Text] [Related]

  • 9. Tacrolimus exposure in the real world: an analysis from the Mycophenolic acid Observational REnal transplant study.
    Shihab FS, Olyaei A, Wiland A, McCague K, Norman DJ.
    Clin Transplant; 2014 Jul; 28(7):768-75. PubMed ID: 24754603
    [Abstract] [Full Text] [Related]

  • 10. Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation.
    Pascual J, Berger SP, Witzke O, Tedesco H, Mulgaonkar S, Qazi Y, Chadban S, Oppenheimer F, Sommerer C, Oberbauer R, Watarai Y, Legendre C, Citterio F, Henry M, Srinivas TR, Luo WL, Marti A, Bernhardt P, Vincenti F, TRANSFORM Investigators.
    J Am Soc Nephrol; 2018 Jul; 29(7):1979-1991. PubMed ID: 29752413
    [Abstract] [Full Text] [Related]

  • 11. The impact of everolimus in reducing cytomegalovirus events in kidney transplant recipients on steroid-avoidance strategy: 3-year follow-up of a randomized clinical trial.
    de Sandes-Freitas TV, Pinheiro PMA, Sales MLMBO, Girão CM, Campos ÉF, Esmeraldo RM.
    Transpl Int; 2018 Dec; 31(12):1345-1356. PubMed ID: 29969826
    [Abstract] [Full Text] [Related]

  • 12. Ten-year observational follow-up of a randomized trial comparing cyclosporine and tacrolimus therapy combined with steroid withdrawal in living-donor renal transplantation.
    Kim J, Park J, Hwang S, Yoo H, Kim K, Park JB, Jang HR, Lee JE, Kim SJ, Kim YG, Kim DJ, Oh HY, Huh W.
    Clin Transplant; 2018 Sep; 32(9):e13372. PubMed ID: 30080284
    [Abstract] [Full Text] [Related]

  • 13. Five-year outcomes in kidney transplant patients randomized to everolimus with cyclosporine withdrawal or low-exposure cyclosporine versus standard therapy.
    Sommerer C, Duerr M, Witzke O, Lehner F, Arns W, Kliem V, Ackermann D, Guba M, Jacobi J, Hauser IA, Stahl R, Reinke P, Rath T, Veit J, Mehrabi A, Porstner M, Budde K, HERAKLES Study Group.
    Am J Transplant; 2018 Dec; 18(12):2965-2976. PubMed ID: 29722128
    [Abstract] [Full Text] [Related]

  • 14. Prospective randomized study comparing everolimus and mycophenolate sodium in de novo kidney transplant recipients from expanded criteria deceased donor.
    Ferreira AN, Felipe CR, Cristelli M, Viana L, Mansur J, de Paula M, Wagner D, de Marco R, Gerbase-DeLima M, Proença H, Aguiar W, Medina-Pestana J, Tedesco-Silva Junior H.
    Transpl Int; 2019 Nov; 32(11):1127-1143. PubMed ID: 31278785
    [Abstract] [Full Text] [Related]

  • 15. Conversion from tacrolimus-mycophenolate mofetil to tacrolimus-mTOR immunosuppression after kidney-pancreas transplantation reduces the incidence of both BK and CMV viremia.
    Knight RJ, Graviss EA, Nguyen DT, Kuten SA, Patel SJ, Gaber L, Gaber AO.
    Clin Transplant; 2018 Jun; 32(6):e13265. PubMed ID: 29676018
    [Abstract] [Full Text] [Related]

  • 16. Clinical significance of tacrolimus intra-patient variability on kidney transplant outcomes according to pre-transplant immunological risk.
    Kim EJ, Kim SJ, Huh KH, Kim BS, Kim MS, Kim SI, Kim YS, Lee J.
    Sci Rep; 2021 Jun 09; 11(1):12114. PubMed ID: 34108576
    [Abstract] [Full Text] [Related]

  • 17. Pilot Randomized Trial of Tacrolimus/Everolimus vs Tacrolimus/Enteric-Coated Mycophenolate Sodium in Adult, Primary Kidney Transplant Recipients at a Single Center.
    Ciancio G, Tryphonopoulos P, Gaynor JJ, Guerra G, Sageshima J, Roth D, Chen L, Kupin W, Mattiazzi A, Tueros L, Flores S, Hanson L, Powell RH, Ruiz P, Vianna R, Burke GW.
    Transplant Proc; 2016 Jun 09; 48(6):2006-10. PubMed ID: 27569936
    [Abstract] [Full Text] [Related]

  • 18. Early Conversion From Calcineurin Inhibitor- to Everolimus-Based Therapy Following Kidney Transplantation: Results of the Randomized ELEVATE Trial.
    de Fijter JW, Holdaas H, Øyen O, Sanders JS, Sundar S, Bemelman FJ, Sommerer C, Pascual J, Avihingsanon Y, Pongskul C, Oppenheimer F, Toselli L, Russ G, Wang Z, Lopez P, Kochuparampil J, Cruzado JM, van der Giet M, ELEVATE Study Group.
    Am J Transplant; 2017 Jul 09; 17(7):1853-1867. PubMed ID: 28027625
    [Abstract] [Full Text] [Related]

  • 19. Prospective clinical trial comparing two immunosuppressive regimens, tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine, in de novo renal transplant recipients: results at 6 months follow-up.
    Favi E, Citterio F, Spagnoletti G, Gargiulo A, Delreno F, Romagnoli J, Castagneto M.
    Transplant Proc; 2009 May 09; 41(4):1152-5. PubMed ID: 19460503
    [Abstract] [Full Text] [Related]

  • 20. Reduced Incidence of Cytomegalovirus Infection in Kidney Transplant Recipients Receiving Everolimus and Reduced Tacrolimus Doses.
    Tedesco-Silva H, Felipe C, Ferreira A, Cristelli M, Oliveira N, Sandes-Freitas T, Aguiar W, Campos E, Gerbase-DeLima M, Franco M, Medina-Pestana J.
    Am J Transplant; 2015 Oct 09; 15(10):2655-64. PubMed ID: 25988935
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.